Evidence map›Paper›PMID 31620822›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2020

Protective effect of chrysin on cyclophosphamide-induced hepatotoxicity and nephrotoxicity via the inhibition of oxidative stress, inflammation, and apoptosis.

Yusuf Temel, Sefa Kucukler, Serkan Yıldırım, Cuneyt Caglayan, Fatih Mehmet Kandemir

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 146 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yusuf TemelDepartment of Solhan School of Health Services, Bingol University, Bingol, Turkey.
Sefa KucuklerDepartment of Biochemistry, Faculty of Veterinary Medicine, Ataturk University, Erzurum, Turkey.
Serkan YıldırımDepartment of Pathology, Faculty of Veterinary Medicine, Ataturk University, Erzurum, Turkey.
Cuneyt CaglayanDepartment of Biochemistry, Faculty of Veterinary Medicine, Bingol University, 12000, Bingol, Turkey. ccaglayan@bingol.edu.tr.ORCID http://orcid.org/0000-0001-5608-554X
Fatih Mehmet KandemirDepartment of Biochemistry, Faculty of Veterinary Medicine, Ataturk University, Erzurum, Turkey.
Atatürk University · TRBingöl University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclophosphamide (CYP) is a chemotherapeutic agent used in the treatment of autoimmune disorders and malignant diseases. However, its usage is restricted due to its severe side effects, especially hepatotoxicity and nephrotoxicity. This study aimed to investigate the protective role of chrysin (CH) against CYP-induced hepatotoxicity and nephrotoxicity in rats. In the present study, 35 male Wistar rats were randomly divided into 5 groups with each group consisting of 7 rats. The rats were pretreated with CH orally in doses of 25- and 50-mg/kg body weight for 7 consecutive days, and CYP (200-mg/kg body weight, i.p.) was administrated on the 7th day 1 h after the last dose of CH. It was found that CH could ameliorate CYP-induced elevations of ALT, ALP, AST, urea, creatinine, MDA, and hepatorenal deterioration, and enhance antioxidant enzymes' activities such as SOD, CAT, and GPx, and GSH's level. Furthermore, CH reversed the changes in levels of inflammatory, apoptotic, and autophagic parameters such as NF-κB, TNF-α, IL-1β, IL-6, iNOS, COX-2, Bax, Bcl-2, and LC3B in liver and kidney tissues. To conclude, the findings of this study demonstrated that CH has a protective effect against CYP-induced hepatorenal toxicity.

Indexed as

Acute Kidney InjuryAnimalsApoptosisChemical and Drug Induced Liver InjuryCyclophosphamideFlavonoidsInflammation MediatorsMaleOxidative StressRandom AllocationRatsRats, WistarchrysinCyclophosphamideFlavonoidsInflammation MediatorsApoptosisChrysinCyclophosphamideHepatotoxicityInflammationNephrotoxicity

Identifiers

PMID31620822
OpenAlexW2980866784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.